转pGH基因猪血清pGH含量的分析

用ELISA方法分别测定了3头F0代成年阳性猪和8头F1代幼年阳性猪血清 pGH的水平,发现阳性个体间在激素含量及变化趋势上有很大差别,其中F1代个体pGH变化趋势与阴性对照较为一致。研究结果表明阳性个体本身性别及生理状况与外源基因表达有关,同时也反映出外源 pGH基因的表达状况与该基因在宿主基因组中的插入位点不同有着密切的联系。     

转pGH基因猪外源基因染色体定位研究

应用地高辛标记探针对转pGH基因(猪生长激素基因)猪染色体进行原位杂交,经胶体金抗体、银增强放大系统检测外源pGH基因在染色体上的整合位点。研究表明,转基因阳性个体间外源基因整合位点存在差异,但对个体而言,外源基因总是集中分布于某一特定的染色体上。本研究将为探究外源基因整合位点与其表达效率的关系及今后定点整合的研究提供理论指导。     

GHR基因敲除香猪的鉴定及生长指标测定

为获得纯合的GHR基因敲除香猪的种群,本研究以贵州从江香猪为母本,中国农业大学提供的GHR基因敲除猪(GHR(+/-))为父本杂交选育F1代,筛选出F1代阳性杂合子猪和阴性猪,再用F1代阳性杂合子猪进行扩繁得到F2代。测定F1代和F2代猪的生长指标,同时检测F1代和F2代阳性猪。实验结果表明F1代GHR基因敲除阳性猪(GHR+/+)和阴性猪(GHR+/-)生长指标差异均不显著(p0.05)。F2代GHR基因敲除猪在3月龄时体长、体重存在显著差异(p0.05),F2代4月龄阳性猪与阴性猪各项指标均差异显著(p0.05)。测序结果显示F1阳性杂合子猪共11头,阴性猪15头;F2阳性纯合子猪共8头,阴性猪9头。     

睾丸注射法制备携带猪PID1基因的转基因兔

目的研究磷酸酪氨酸互作结构域1(PID1)基因与肌内脂肪含量的关系,探究睾丸注射法在转基因动物制备中的可行性。方法将携带猪PID1基因的重组质粒pIRES2-acGFP-PID1与转染试剂共孵育后,对新西兰兔进行了睾丸打点注射试验。对繁殖的F1代个体进行了活体荧光检测、PCR和western blotting检测,以及抽样屠宰进行肌内脂肪含量等检测;将F1代阳性个体互交,繁殖了F2代兔,对其进行了阳性率检测以及肌内脂肪含量检测。结果外源PID1基因和荧光蛋白基因在后代中均成功表达,其中,F1代阳性率为35.88%,F2代阳性率为34.33%;转基因阳性兔与阴性和空白对照兔相比,PID1蛋白表达水平有所增加,肌内脂肪含量有显著提高(P0.05)。结论 PID1基因与肌内脂肪沉积密切相关,同时,进一步证明了睾丸注射法可以用于制备转基因动物,且外源基因可以稳定遗传。     

腺病毒介导的含第一内含子pGH cDNA在CHO细胞中的表达

通过同源重组的方法分别构建了在CMV启动子控制下的带有第一内含子和不带内含子的pGH cDNA基因的重组腺病毒。通过感染CHO细胞表明,构建的重组腺病毒能够介导pGH基因在CHO细胞中表达,加入第一内含子的pGH cDNA基因的表达效率比不加内含子的提高了117％,这说明pGH基因的第一内含子有促进该基因在真核细胞中表达的功能。     

转基因猪体内外源基因的整合鉴定

外源猪生长激素基因被导入湖北白猪．为避免羊、猪之间在金属硫蛋白启动上的同源性而造成PCR检测结果的假阳性,分别将PCR合成反应的两个引物设计在羊金属硫蛋白基因启动子一侧和猪生长激素一侧,使PCR合成反应的结果特异地反映外源基因的整合性,准确地鉴定出转基因猪．DNA印迹分析结果表明,43头待检仔猪中有6头呈外源基因整合阳性．     

肝组织特异表达人核受体nr5a2转基因小鼠的构建

人乙肝病毒增强子ⅡB1结合因子（hB1F）系Ftz—F1（NR5A）亚家族的新成员。经基因重组法将人hb1 fcDNA置于小鼠白蛋白增慢子／启动子序列下游构建成肝特异重组载体,通过原核显微注射将该载体导入小鼠受精卵原核,经注射且状态良好的卯回输至假孕母鼠输卯管。产下仔鼠经PCR和Southern blotting鉴定,同时RT—PCR和Western blotting分析转基因的表达。阳性Founder鼠与正常C57鼠交配以建立转基因纯系小鼠,F1代以PCR法鉴定。结果共获得4只PCR鉴定转基因阳性Founder鼠,其中一只同时经Southern blotting鉴定为阳性。RT—PCR和Western blotting结果显示,外源基因在转基因小鼠的肝组织成功表达。遗传学分析表明,转基因已整合入小鼠基因组并可稳定溃传。     

转基因红鲤体细胞的核移植

以F4代转hGH基因红鲤体细胞（肾脏和尾鳍）及培养18代的F4代转hGH基因红鲤尾鳍细胞为核供体,泥鳅或黄河鲤成熟卵为受体,进行了核移植,以探讨外源F4代转基因鱼体外源基因的分布与存在形式,稳定性和克隆转基因鱼的可能性。F4代红鲁肾脏细胞核与泥鳅卵配合的核移植胚胎有12．4％发育到囊胚,0．33％发育到神经胚;F4代尾鳍细胞核移入泥鳅卵后的重组胚发育到囊胚,神经胚、肌节期和肌肉效应期的胚胎分别为24．5％、0．3％、0．2％和0．1％;对照卵无发育。F4代红鲤尾鳍培养细胞与黄河鲤卵子配合的重组胚胎有50．53％发育到囊胚,5．69％发育到原肠胚,0．53％发育到神经胚,0．4％发育到肌节期。说明由于同种细胞核与卵细胞的相容性高于异种核卵的相容性,早期发育率高;而由于培养细胞的异倍化,后期的发育率降低。用PCR技术对供体鱼不同个体及同一体不同组织外源基因检测,结果100％个体为阳性鱼,而且不同组织的阳性率也是100％,说明外源基因均匀分布在不同组织中。无论F4代转基因鱼的肾脏细胞、尾鳍细胞还是培养的尾鳍细胞作核移植供体,核移植胚胎中hGH基因的检出率为100％。说明F4代转基因红鲤个体不同细胞都存在hGH基因,而且经长期培养不会丢失。表明F4代转基因红鲤中的外源hGH基因已基本稳定,体细胞核移植可以作为获得同质化转基因鱼的有效手段,但核移植效率还很低。另外还讨论了核质的相容性、细胞周期的协调、染色体的变异等因素对核移植的影响。     

长白猪×蓝塘猪及其杂种基因组甲基化片段克隆与分析

应用甲基化敏感扩增多态性(MSAP)技术对6头长白公猪和50头蓝塘母猪及5头长白×蓝塘杂交F1代3个群体基因组DNA胞嘧啶甲基化位点进行检测,旨在克隆和分析父母代猪及其杂种F1代之间基因组DNA共同甲基化片段和差异片段,并找到其同源基因.结果显示,从MSAP条带中分离、克隆得到18条3个群体共同的甲基化片段、10条母代独有的甲基化片段和9条杂交一代独有的甲基化片段,其中有1条3个群体共有的甲基化片段通过EST拼接和电子延伸后在NCBI数据库中找到同源基因,即猪类酪氨酸蛋白激酶Lyn基因(GeneID:LOC100152890,序列号:XM_001926250).结果表明,长蓝杂交F1代与其父母代之间的基因组甲基化存在异同,为通过MSAP技术克隆猪基因组DNA甲基化片段及寻找其对应的甲基化基因提供可能,也会为将来研究这些甲基化基因表达调控机制奠定基础.     

庚型肝炎病毒转基因小鼠的建立

利用受精卵原核显微注射的方法,产生了含有HGV结构蛋白C、E1、E2及部分非结构蛋白NS2、NS3的转基因小鼠.得到10只founder小鼠,其中有3只founder小鼠与正常小鼠交配后得到了整合有外源基因的F1代阳性小鼠.RT-PCR的结果显示,外源基因可在founder小鼠及F1代小鼠的血液有核细胞及肝细胞内转录;组织病理学检查显示,某些转基因小鼠的肝细胞出现了水样变、脂肪变性及轻微炎性反应等病理学改变,但与同一品系的正常小鼠相比,转基因小鼠血清转氨酶无明显升高.     

The synthesis and processing of a nuclear RNA precursor to rat pregrowth hormone messenger RNA.

A recombinant DNA plasmid, pBR322-GH1, which contains about 80% of the sequences of rat pregrowth hormone (pGH) mRNA, allowed an analysis of nuclear RNA from GH3 cells for possible precursors of cytoplasmic pGH mRNA. A single 20-22S RNA SPECIES ABOUT 2-3 TIMes larger than pGH mRNA was detected in nuclear RNA from GH3 cells labeled for 5 min. with 3H-uridine. After longer label times a 12S RNA indistinguishable in size from cytoplasmic 12S pGH mRNA became the predominant labeled RNA complementary to the plasmid pBR322-GH1. Both of these nuclear RNA species contained poly (A). Kinetic analysis of the labeling of nuclear and cytoplasmic pGH mRNA sequences showed that the 20S and 12S nuclear RNA molecules were labeled before significant labeling of cytoplasmic pGH mRNA was detected, and also indicated that there is complete conservation of nuclear pGH mRNA sequences in the production of cytoplasmic pGH mRNA. These results indicate that cytoplasmic pGH mRNA is generated by nuclear processing of a larger nuclear RNA molecule.     

Equilibrium denaturation of recombinant porcine growth hormone.

Equilibrium denaturation of recombinant porcine growth hormone (pGH) derived from Escherichia coli using the denaturant guanidine hydrochloride (GuHCl) was followed by ultraviolet absorption spectroscopy, intrinsic fluorescence, far-ultraviolet circular dichroism, and size-exclusion chromatography. The normalized denaturation transition curves for each of the above methods were not coincident; denaturation resulted in an initial disruption of the tertiary structure, whereas secondary structure and degree of compactness were disrupted at higher concentrations of denaturant. Size-exclusion chromatography also detected an associated form of pGH at intermediate GuHCl concentrations. These findings conclusively show that pGH does not follow a simple two-state folding mechanism but are consistent with the framework model of folding. Stable intermediates observed were similar to those seen in other nonhuman growth hormones and are characterized as compact and largely alpha-helical yet lacking nativelike tertiary structure.     

猪生长激素基因在杆状病毒载体系统中的表达

通过对猪生长激素（ｐＧＨ）基因的ｃＤＮＡ进行测序,得到ｐＧＨｃＤＮＡ的全序列,并与Ｓｅｅｂｕｒｇ等报道的序列进行了比较和讨论。然后利用具人工合成启动子和多角体蛋白ＸＩＶ启动子的转移载体质粒ｐＳＸＩＶＶＩ＾＋Ｘ３／４构建出含ｐＧＨ基因的重组质粒ｐＸ３／４－ｐＧＨ。将ｐＸ３／４－ｐＧＨ与致死缺失型线性化ＡｃＭＮＰＶ－ＯＣＣ＾－ＤＮＡ共转染Ｓｆ９细胞,构建出既能形成多角体又能表达ｐＧＨ基因的苜蓿丫纹夜蛾     

Porcine growth hormone gene expression from viral promoters in transgenic swine

Abstract

The production of porcine growth hormone (pGH) from novel expression vectors containing the promoter/enhancer elements of the Moloney murine leukemia virus (MLV) LTR or the human cytomegalovirus (CMV) immediate early gene was examined in transgenic swine. Both fusion genes resulted in elevated levels of serum pGH, elevation of insulin‐like growth factor 1 (IGF‐1), and a pronounced decrease in carcass fat deposition. The two viral promoter/enhancer elements were constitutively active in the transgenic swine throughout the life of the animals. In individual swine, the CMV‐pGH transgene was expressed predominantly in the pancreas while the MLV‐pGH transgene was expressed in a wide variety of tissues. These swine were infertile, had insulin resistance, and demonstrated an accelerated form of osteochondritis dissicans. Our results show that excess pGH produces a phenotype identical to that seen in swine expressing heterologous growth hormones, and provides a baseline for assessing the overall efficiency of producing transgenic swine. Furthermore, our data suggests that unregulated pGH production, even at 15 times normal levels and independent of the tissue source, has adverse effects that outweigh the desired reduction in carcass fat deposition in transgenic swine.     

Enhancement of hormonal activity with a monoclonal antibody specific to porcine growth hormone

Abstract

The potentiation of the biological effects of recombinant porcine growth hormone (pGH) by immunologic manipulation was investigated. A monoclonal antibody (mAb), designated PS‐7.6, was raised against pGH and repeatedly shown to enhance the responsiveness of hypophysectomized (hypox) rats to pGH. As a result, animals receiving a combination treatment of pGH and mAb PS‐7.6 together gained significantly more weight than those receiving the same doses of pGH alone. The enhancing action of the mAb was a rapid process and its effective doses ranged from 0.1 to 2 mg/injection. The ability of the antibody to augment the hormonal activity persisted beyond the 5‐day treatment period and the differences in net weight gain between treated and control animals remained significant for 28 days. Results from treatment frequency studies further suggested that pGH when complexed with mAb PS‐7.6 required fewer injections and produced a greater efficacy than being administered alone. Therefore, present findings suggest that mAb PS‐7.6 may prove useful for not only improving the efficiency of pGH, but also developing a novel formulation for sustained pGH release.     

Plasma lactate, GH and GH-binding protein levels in exercise following BCAA supplementation in athletes

Summary. Branched chain amino acids (BCAA) stimulate protein synthesis, and growth hormone (GH) is a mediator in this process. A pre-exercise BCAA ingestion increases muscle BCAA uptake and use. Therefore after one month of chronic BCAA treatment (0.2 g kg⁻¹ of body weight), the effects of a pre-exercise oral supplementation of BCAA (9.64 g) on the plasma lactate (La) were examined in triathletes, before and after 60 min of physical exercise (75% of VO₂max). The plasma levels of GH (pGH) and of growth hormone binding protein (pGHBP) were also studied. The end-exercise La of each athlete was higher than basal. Furthermore, after the chronic BCAA treatment, these end-exercise levels were lower than before this treatment (8.6 ± 0.8 mmol L⁻¹ after vs 12.8 ± 1.0 mmol L⁻¹ before treatment; p < 0.05 [mean ± std. err.]). The end-exercise pGH of each athlete was higher than basal (p < 0.05). Furthermore, after the chronic treatment, this end-exercise pGH was higher (but not significantly, p = 0.08) than before this treatment (12.2 ± 2.0 ng mL⁻¹ before vs 33.8 ± 13.6 ng mL⁻¹ after treatment). The end-exercise pGHBP was higher than basal (p < 0.05); and after the BCAA chronic treatment, this end-exercise pGHBP was 738 ± 85 pmol L⁻¹ before vs 1691 ± 555 pmol L⁻¹ after. pGH/pGHBP ratio was unchanged in each athlete and between the groups, but a tendency to increase was observed at end-exercise. The lower La at the end of an intense muscular exercise may reflect an improvement of BCAA use, due to the BCAA chronic treatment. The chronic BCAA effects on pGH and pGHBP might suggest an improvement of muscle activity through protein synthesis. Received January 5, 1999 / Accepted June 17, 1999     

Productivity improvement of recombinant <Emphasis Type="Italic">Escherichia coli</Emphasis> fermentation via robust optimization

A nonlinear model of a recombinant Escherichia coli producing porcine growth hormone (pGH) fermentation was developed. The model was used to calculate a glucose feeding and temperature strategy to optimize the production of pGH. Simulations showed that the implementation of optimal feed and temperature profiles was sensitive to the maximum specific growth rate, and a mismatch could result in excessive acetate production and a significant reduction in pGH yield. An optimization algorithm was thus developed, using feedback control, to counter the effects of uncertainty in the specific growth rate and thus determine an optimal operating strategy for pGH production. This policy was experimentally implemented in a 10 L fermenter and resulted in a 125% increase in productivity over the previous best experimental result with this system—in spite of significant plant-model mismatch.